The ubiquitin-proteosome pathway is an area that is increasingly becoming appreciated as one of the most promising targets of drug discovery efforts to emerge in the last decade and this volume provides, for the first time, a centralized summary of groundbreaking research from numerous research centers that have participated in the development of this novel class of pharmacologic agents. Part I reviews the chemistry and cell biology of the proteasome while part II reviews the rational for proteasome inhibition in cancer. Part III reviews the clinical trial program of proteasome inhibitors in a variety of tumor types

The ubiquitin-proteosome pathway is an area that is increasingly becoming appreciated as one of the most promising targets of drug discovery efforts to emerge in the last decade and this volume provides, for the first time, a centralized summary of groundbreaking research from numerous research centers that have participated in the development of this novel class of pharmacologic agents. Part I reviews the chemistry and cell biology of the proteasome while part II reviews the rational for proteasome inhibition in cancer. Part III reviews the clinical trial program of proteasome inhibitors in a variety of tumor types